Recruiting

Recurrence Monitoring

Sponsor:

Scripps Translational Science Institute

Code:

NCT03878537

Conditions

Non Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

This research study is investigating the role of cell free tumor DNA profiling in determining disease relapse and/or progression for patients with advanced NSCLC.

Conditions

Non Small Cell Lung Cancer

Study ID

NCT03878537

Start date

Mar 14, 2019

Status verified date

Mar, 2021

Completion date

Dec 31, 2021

Anticipated

Primary completion date

Mar 1, 2021

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Treatment naïve biopsy confirmed not surgically resectable stage III or greater NSCLC
  • Baseline CT imaging available

Exclusion Criteria:

  • Patients unable to undergo biopsy for initial tissue diagnosis
  • Patients who do not wish to pursue standard of care therapy
  • Patients with another diagnosis of malignancy

Study Design

Enrollment

50 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Progression Free Survival [ Time Frame: 24 months ]
  • Progression Free Survival [ Time Frame: 24 months ]

Central Contacts and Locations

Central contacts

Aditya Sarvaria

619-849-4469Sarvaria.Aditya@scripsshealth.org

Marin Xavier

619-849-4469Xavier.Marin@scrippshealth.org

Locations

Scripps Health/Scripps Clinic Hillcrest/Scripps Clinic Torrey Pines

Recruiting

San Diego, California, United States, 92103

Contacts

Marin Xavier

619-849-4469Xavier.Marin@scrippshealth.org

Shannon Fortin Ensign

858-784-2157FortinEnsign.Shannon@scrippshealth.org

More Information

Sponsor

Scripps Translational Science Institute

Last update posted

Mar 23, 2021

Last verified

Mar, 2021

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Scripps Translational Science Institute on 2021-03-23.